香港股市 將在 2 小時 7 分鐘 開市

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
31.92-0.36 (-1.12%)
收市:04:00PM EST
31.92 0.00 (0.00%)
收市後: 05:20PM EST

Genmab A/S

Kalvebod Brygge 43
Copenhagen 1560
Denmark
45 70 20 27 28
https://www.genmab.com

版塊Healthcare
行業Biotechnology
全職員工2,132

高階主管

名稱頭銜支付行使價出生年份
Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO2.72M1961
Mr. Anthony PaganoExecutive VP & CFO1.01M1978
Mr. Anthony ManciniExecutive VP & COO1.1M1971
Mr. Martin SchultzSenior Director of Clinical Operations & Non-Independent Director72.36k1976
Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer1.14M1958
Dr. Tahamtan AhmadiExecutive VP, Chief Medical Officer & Head of Experimental Medicines1.09M1973
Dr. Mijke Zachariasse Ph.D.Senior Director, Head of Antibody Research Materials & Non-Independent Director144.71k1974
Mr. Takahiro HamataniSenior Director of Finance Japan & Non-Independent Director72.36k1975
Mr. Andrew CarlsenSenior Director, VP & Head of Investor Relations
Ms. Birgitte Stephensen M.Sc.Executive VP & Chief Legal Officer1961
截止 2022年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

公司管治

截至 2023年12月1日 止,Genmab A/S 的 ISS 管治質素評分為 3。 Pillar 分數正在審核中:2;董事會:1;股東權利:1;現金賠償:9。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。